Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
s-oxprenolol
- Development stage
- Unknown
- Lead developer
- Actimed Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
S-oxprenolol (ACM-002) is the S-enantiomer of the non-selective beta-adrenergic receptor antagonist oxprenolol. It is being developed by Actimed Therapeutics for the treatment of muscle wasting (cachexia) associated with amyotrophic lateral sclerosis (ALS) and other chronic conditions. S-oxprenolol is designed to address the multifactorial nature of cachexia by combining beta-blocking activity with potential anabolic and anti-catabolic effects. By antagonizing beta-1 and beta-2 adrenergic receptors, it aims to reduce the high metabolic rate and systemic inflammation that drive muscle loss. Actimed has licensed the global rights for S-oxprenolol to Faraday Pharmaceuticals for all indications except ALS, for which Actimed retains development rights and has received US Orphan Drug Designation.
- Other names
- (S)-oxprenolol
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)ADRB1 (β1)ADRB2 (β2)ADRB3 (β3)
Beyond the preview
Go deeper on s-oxprenolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on s-oxprenolol.